Subscribe
Be the first with the news that moves the market- Datametrex AI Limited (DM) has received authorization for its COVID19 Rapid antigen test kit in Canada
- Health Canada granted the approval of the antigen point-of-care rapid test device under the Interim Order
- Datametrex made the application for the PCL Antigen under IO on August 24, 2020
- PCL Antigen has a test sensitivity of 94.29 per cent and the test kits are suitable for point of care tests, according to the manufacturer
- Datametrex is up 17.31 per cent on the day, with shares of the company trading at C$ 0.30 at 11:10 am ET
Datametrex AI Limited (DM) has received authorization for its COVID19 Rapid antigen test kit in Canada.
Health Canada granted the approval of the antigen point-of-care rapid test device under the Interim Order.
Datametrex made the application for the PCL Antigen under IO on August 24, 2020.
PCL Antigen has a test sensitivity of 94.29 per cent and the test kits are suitable for point of care tests, according to the manufacturer.
The tests are relatively simple to administer and no extra equipment is needed. Results are available in 10 minutes. Early detection using rapid tests will also provide further protection to Canada’s front-line workers, according to the company.
“Datametrex has been given another incredible opportunity to sell an additional medical testing device in Canada with the antigen test, with a supplier with outstanding medical devices in PCL. With the highly contagious new variant, and the second wave and possible third wave of COVID-19 in Canada and throughout the world, Datametrex believes an increase in testing capacity is critical to test and protect people,” said Datametrex AI Limited CEO Marshall Gunter.
Datametrex cautions that its ability to fulfill any purchase order for the PCL Rapid test kits is subject to the availability of inventory at the time of order.
Due to the extraordinarily high demand, there is volatility in the supply chain and available supply may fluctuate on a daily basis.
Datametrex anticipates that it will have little, or no upfront costs associated with importing and selling these test kits.
Datametrex is up 17.31 per cent on the day, with shares of the company trading at C$ 0.30 at 11:10 am ET.
